16.19
+0.44(+2.79%)
Currency In USD
Address
3415 Colorado Avenue
Boulder, CO 80303
United States of America
Phone
303 735 8373
Website
Sector
Healthcare
Industry
Biotechnology
Employees
117
First IPO Date
March 26, 2021
| Name | Title | Pay | Year Born |
| Dr. Kevin Koch Ph.D. | President, Chief Executive Officer & Director | 1.07M | 1960 |
| Mr. R. Michael Carruthers | Chief Financial Officer | 386,009 | 1958 |
| Dr. Alan J. Russell Ph.D. | Co-Founder, Chief Scientific Officer & Director | 657,520 | 1970 |
| Dr. Behrad Derakhshan Ph.D. | Chief Operating Officer | 796,536 | 1980 |
| Dr. Joanne M. Donovan M.D., Ph.D. | Chief Medical Officer | 824,817 | 1957 |
| Dr. Robert Blaustein M.D., Ph.D. | Chief Development Officer | 0 | 1961 |
| Mr. John R. Moore J.D. | General Counsel | 0 | 1964 |
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
